The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
C-Reactive Protein and Prediction of 1-Year Mortality in Prevalent Hemodialysis Patients
Open accessAbstract
BACKGROUND AND OBJECTIVES: Measurement of C-reactive protein (CRP) levels remains uncommon in North America, although it is now routine in many countries. Using Dialysis Outcomes and Practice Patterns Study data, our primary aim was to evaluate the value of CRP for predicting mortality when measured along with other common inflammatory biomarkers. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied 5061 prevalent hemodialysis patients from 2005 to 2008 in 140 facilities routinely measuring CRP in 10 countries. The association of CRP with mortality was evaluated using Cox regression. Prediction of 1-year mortality was assessed in logistic regression models with differing adjustment variables. RESULTS: Median baseline CRP was lower in Japan (1.0 mg/L) than other countries (6.0 mg/L). CRP was positively, monotonically associated with mortality. No threshold below which mortality rate leveled off was identified. In prediction models, CRP performance was comparable with albumin and exceeded ferritin and white blood cell (WBC) count based on measures of model discrimination (c-statistics, net reclassification improvement [NRI]) and global model fit (generalized R(2)). The primary analysis included age, gender, diabetes, catheter use, and the four inflammatory markers (omitting one at a time). Specifying NRI ≥5% as appropriate reclassification of predicted mortality risk, NRI for CRP was 12.8% compared with 10.3% for albumin, 0.8% for ferritin, and <0.1% for WBC. CONCLUSIONS: These findings demonstrate the value of measuring CRP in addition to standard inflammatory biomarkers to improve mortality prediction in hemodialysis patients. Future studies are indicated to identify interventions that lower CRP and to identify whether they improve clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · cited 2×
“, for secondary cardiovascular prevention) (24).”
ResultAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M., & Cook, N. R. (2008) · Circulation · doi:10.1161/circulationaha.108.814251 · Cited by 841
The effect of including C-reactive protein in cardiovascular risk prediction models for women
Cook, N. R., Buring, J. E., & Ridker, P. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00128 · Cited by 504 · cited 1×
“Given this limitation, we also applied risk reclassification to quantify the extent to which risk classification is improved with the addition of the marker of interest (17,18,25,27).”
MethodBiochemistry and Biomarkers of Inflamed Patients: Why Look, What to Assess
Kaysen, G. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03090509 · Cited by 100
Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
Elliott, P. (2009) · JAMA · doi:10.1001/jama.2009.954 · Cited by 35
Cited by
Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome
Mihai, S., Codrici, E., Popescu, I. D., Enciu, A.-M., Albulescu, L., Necula, L. G., Mambet, C., Anton, G., & Tanase, C. (2018) · Journal of Immunology Research · doi:10.1155/2018/2180373 · Cited by 673
Update on Inflammation in Chronic Kidney Disease
Akchurin, O. M., & Kaskel, F. (2015) · Blood Purification · doi:10.1159/000368940 · Cited by 603
Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010263 · Cited by 519
McAdams‐DeMarco, M. A., Law, A., Salter, M. L., Boyarsky, B., Gimenez, L., Jaar, B. G., Walston, J. D., & Segev, D. L. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12266 · Cited by 448
C-reactive protein and Hypertension
Hage, F. G. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.111 · Cited by 205
Metadata
- Authors
- Bazeley, J., Bieber, B., Li, Y., Morgenstern, H., de Sequera, P., Combe, C., Yamamoto, H., Gallagher, M., Port, F. K., & Robinson, B. M.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2011-10
- Volume
- 6
- Issue
- 10
- Pages
- 2452-2461
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2149147910
- Cited by
- 175
- References
- 10
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.